1. Alzheimer’s Association, Alzheimer’s disease facts and figures, 2014, 10, 2, available at http://www.alz.org/downloads/Facts_Figures_2014.pdf
2. Holtzman D.M., Morris J.C., Goate A.M., Alzheimer’s disease: the challenge of the second century, Sci. Transl. Med., 2011, 3, 77sr1
3. Ono K., Yamada M., Low-n oligomers as therapeutic targets of Alzheimer’s disease, J. Neurochem., 2011, 117, 19–28
4. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I., Tau in Alzheimer disease and related tauopathies, Curr. Alzheimer Res., 2010, 7, 656–664
5. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome, Neuron, 2004, 43, 321–332